Gut-Brain-On-Chip Modeling Service

Creative Biolabs provides custom Gut-Brain-On-Chip Modeling Services for research teams that need to examine how intestinal barrier events, microbial products or metabolites, immune mediators, vascular transport, blood-brain barrier (BBB) function, and neural responses influence one another under controlled human-relevant conditions.

The service supports mechanism-of-action studies, microbiome-derived signal testing, barrier permeability and disruption studies, neuroinflammation research, orally administered drug assessment, candidate efficacy comparison, and safety evaluation. We can assist with chip architecture, cell-source and compartment selection, flow and exposure optimization, barrier qualification, perturbation design, longitudinal sampling, multi-endpoint analysis, and an interpretation-ready data package.

Custom Gut-Brain-On-Chip Studies

A useful gut-brain model does not attempt to include every possible cell type. It includes the minimum set of interfaces required to test a defined route of communication. A permeability question may require intestinal epithelium, a vascular channel, and a BBB module. A neuroimmune question may additionally require microglia or astrocytes, whereas a metabolism study may prioritize enteroendocrine cells, microbial metabolites, and neural activity. We define the causal sequence, exposure direction, sampling locations, and primary decision before selecting the modules.

Projects can be designed to answer questions such as:

• Barrier-to-brain signaling: Does a gut-side perturbation alter intestinal permeability, vascular mediators, BBB integrity, and neuronal or glial state in a temporally coherent sequence?
• Microbiome-relevant mechanisms: How do short-chain fatty acids, LPS, bacterial extracellular vesicles, tryptophan metabolites, bile acids, or project-specific microbial products influence downstream neural biology?
• Therapeutic intervention: Can a gut-targeted, barrier-protective, anti-inflammatory, neuroprotective, or microbiome-modulating candidate interrupt the selected signaling pathway?
• Drug disposition and safety: Does an orally relevant test article cross the intestinal and BBB interfaces, and does exposure produce neural efficacy or off-target toxicity?
• Patient-relevant modeling: Would donor-derived or isogenic iPSC cells reveal genotype-, disease-, or patient-specific differences in the response?

The study can be connected with our organ-on-chip modeling service, iPSC-derived BBB model generation service, and brain organoid modeling service.

Configure the Gut, Vascular, BBB, and Neural Modules

Platform complexity is matched to the intended inference. Cell source, donor background, differentiation state, extracellular matrix, channel geometry, membrane characteristics, flow rate, medium compatibility, compartment volume, sampling access, adsorption risk, and experiment duration are considered together. Each added module must contribute a measurable variable or a necessary biological barrier.

Gut and Microbiome-Facing Compartment

The gut module can use a scalable epithelial cell model for screening or a primary, enteroid-, organoid-, or iPSC-derived interface when cellular diversity and donor relevance are central. Optional goblet or enteroendocrine components can support mucus and hormone measurements. Live-microbe studies require careful oxygen, contamination, residence-time, and compatibility controls; many projects are better served by sterile microbial metabolites, lysates, vesicles, or conditioned media.

Neural and Neurovascular Compartment

The neural side can incorporate enteric, sensory, cortical, dopaminergic, or other project-aligned neurons, with astrocytes or microglia where inflammatory crosstalk is important. Neural spheroids or organoids extend cellular organization and exposure duration. A BBB module can add brain microvascular endothelial cells, pericytes, and astrocytes to distinguish vascular transport from direct neural exposure. Complex neural models may be developed through our microglia-containing brain organoid modeling service or supported with iPSC-derived microglia generation.

Model Gut-Derived Signals and Disease-Relevant Stressors

A perturbation is introduced at the compartment where it would first act in vivo. Directionality matters: a luminal exposure, vascular exposure, immune-cell challenge, or direct neural treatment answers a different question. Pilot experiments establish a non-destructive but measurable window, verify recovery of the dosed material, and identify when upstream and downstream endpoints should be sampled.

• Microbial metabolites and products: Short-chain fatty acids, LPS, peptidoglycan, indoles, bile-acid derivatives, neurotransmitter-related metabolites, extracellular vesicles, or defined mixtures can be dosed individually or in rational combinations.
• Inflammatory signaling: Cytokines, immune-cell trafficking, epithelial injury, oxidative stress, or disease-relevant inflammatory media can be used to trace barrier and neuroimmune responses.
• Dietary and endocrine cues: Nutrients, food-derived compounds, GLP-1/PYY-related signaling, or metabolically relevant stimuli can be examined for enteroendocrine and neural effects.
• Neurological disease context: PD, AD, mood-disorder, neurodevelopmental, or pain-related hypotheses can be modeled with selected disease cells, pathological proteins, genetic backgrounds, or inflammatory stressors.
• Therapeutic candidates: Small molecules, biologics, peptides, oligonucleotides, microbial interventions, metabolites, drug-delivery systems, or combination regimens can be evaluated.

Neuroinflammatory consequences may be extended with the microglia phagocytosis assay and related glial profiling.

Connect Barrier, Molecular, Immune, and Neural Readouts

The endpoint plan is organized as a causal evidence chain. Upstream measurements confirm that the gut-side exposure changed the intended interface; intermediate measurements identify transported mediators and BBB effects; downstream measurements determine whether neural cells were functionally altered. Time-resolved sampling helps separate exposure, signaling, injury, and recovery.

• Intestinal barrier: TEER or impedance, fluorescent tracer permeability, tight-junction localization, epithelial morphology, mucus, transporter activity, viability, and inflammatory signaling.
• Vascular and BBB function: Barrier resistance, paracellular permeability, endothelial junctions, transporter activity, activation markers, and analyte appearance in the receiving compartment.
• Secreted and metabolic signals: Cytokines, chemokines, hormones, neurotransmitter-related metabolites, short-chain fatty acids, bile acids, targeted metabolites, or discovery proteomic/metabolomic panels.
• Neuronal health and structure: Cell survival, neurite morphology, synaptic markers, mitochondrial stress, oxidative injury, disease-associated proteins, and high-content image phenotypes.
• Neural function: Calcium dynamics, spontaneous or evoked electrical activity, neurotransmitter release, network synchrony, and stimulus-response behavior.
• Glial and immune response: Microglial or astrocytic morphology, activation markers, phagocytosis, inflammasome-related signals, cytokine release, and immune-cell adhesion or migration.

Functional neural measurements can be supported by the calcium imaging assay service and neuronal MEA assay service.

Applications in Mechanism and Therapeutic Development

• Gut-first neurodegeneration: Test whether gut barrier disruption, inflammatory mediators, microbial metabolites, or pathological proteins alter BBB and neuronal phenotypes relevant to Parkinson's or Alzheimer's disease.
• Neuroinflammation and immune crosstalk: Determine whether a gut-side signal activates endothelium, recruits immune cells, or changes microglial and astrocytic state.
• IBS, IBD, and visceral signaling: Connect intestinal epithelial or inflammatory changes with enteric, sensory, or central neuronal responses.
• Metabolic and appetite regulation: Evaluate enteroendocrine hormones and metabolites that influence appetite, satiety, energy balance, or neural circuits.
• Oral drug assessment: Measure intestinal permeability, vascular exposure, BBB passage, neural pharmacology, and organ-specific toxicity within one coordinated system.
• Biomarker and mechanism discovery: Use serial effluent collection and multi-omic analysis to identify mediators that track with barrier or neural outcomes.

Related Research

These studies illustrate two complementary design principles: a gut-brain model should represent the relevant communication routes and barriers, and an integrated chip should qualify each tissue interface before using downstream neural effects to support a mechanistic or therapeutic conclusion.

Mapping the Biological Routes a Gut-Brain Chip Must Represent

Hall and Bendtsen summarized the gut microbiome, intestinal barrier, systemic circulation, BBB, enteric nervous system, endocrine signals, immune mediators, and central neural tissue as interconnected elements of the gut-brain axis. Their framework is useful for model scoping: each proposed mechanism should be translated into a defined donor compartment, transport path, receiving compartment, and measurable response rather than represented by a generic co-culture.

Fig. 1 Biological routes and barriers of the gut-brain axis.^1,3

An Integrated Chip Links Gut-Derived LPS, Butyrate, and BBB Function

Yan and colleagues reported a multicellular, three-dimensional gut-brain interaction chip incorporating intestinal and BBB models under microfluidic flow. The study compared chip and static conditions, evaluated barrier and transporter performance, and used gut-derived LPS with butyrate intervention to investigate how an upstream intestinal event affects downstream BBB function. The design demonstrates why interface qualification, directional exposure, and barrier-specific readouts are essential before interpreting a brain-side response.

Fig. 2 Design and fabrication concept for an integrated human gut-brain interaction chip.^2,3

Frequently Asked Questions

1. What can a gut-brain-on-chip model investigate?

   The model can investigate how intestinal barrier changes, microbial products or metabolites, immune mediators, endocrine signals, vascular transport, and BBB function influence neuronal or glial outcomes. It can support mechanistic studies, disease modeling, permeability, drug efficacy, biomarker discovery, and safety evaluation.

2. Which cell types can be included?

   Configurations may include intestinal epithelial cells, goblet or enteroendocrine cells, vascular endothelial cells, brain microvascular endothelial cells, pericytes, enteric or sensory neurons, CNS neurons, astrocytes, microglia, neural spheroids, or brain organoids. Cell selection is determined by the communication route and study endpoint.

3. Can patient-derived iPSC cells be used?

   Yes. Patient-derived, healthy-donor, or isogenic iPSC-derived intestinal, neural, glial, or BBB-related cells can be considered when donor background or genotype is important. Differentiation maturity, batch qualification, medium compatibility, and experiment duration are assessed during feasibility planning.

4. Can the platform include live microbiota?

   Selected live-microbe experiments may be feasible when oxygen, residence time, contamination control, medium compatibility, and tissue tolerance can be managed. For many mechanism studies, sterile metabolites, microbial products, extracellular vesicles, lysates, or conditioned media provide better control and reproducibility.

5. How are intestinal and BBB barriers qualified?

   Barrier qualification can combine TEER or impedance, tracer permeability, junction-protein localization, morphology, viability, and transporter-related measurements. Acceptance criteria are set for each module before the integrated perturbation or candidate study begins.

6. Can orally administered drug candidates be evaluated?

   Yes. The platform can examine intestinal permeability, vascular appearance, BBB passage or disruption, downstream neural pharmacology, and compartment-specific toxicity. Recovery and adsorption controls are important because microfluidic materials and tubing can alter apparent exposure.

7. Which controls are recommended?

   Typical controls include untreated baseline, vehicle, stressor or disease condition, positive or reference control, test article without stressor, permeability controls, and independent module controls. Sampling blanks, recovery controls, viability measurements, and time-matched chip controls may also be included.

8. What information is needed to start a custom study?

   Helpful starting information includes the biological hypothesis, initiating and receiving compartments, preferred cell sources, microbial or test article details, intended exposure route, expected concentration and duration, primary endpoint, required throughput, available comparators, and the decision the data must support. A feasibility pilot can resolve undefined parameters.

References

1. Hall, Vanessa, and Katja Maria Sahlgren Bendtsen. "Getting Closer to Modeling the Gut-Brain Axis Using Induced Pluripotent Stem Cells." Frontiers in Cell and Developmental Biology, vol. 11, 2023, article 1146062. https://doi.org/10.3389/fcell.2023.1146062
2. Yan, Ranran, et al. "Human Gut-Brain Interaction Chip for Dissecting the Gut-Derived LPS and Butyrate Regulation of the Blood-Brain Barrier." Biosensors, vol. 16, no. 1, 2026, article 23. https://doi.org/10.3390/bios16010023
3. Distributed under Open Access license CC BY 4.0, without modification.